Phase IIa clinical trail of hemocoagulase acutus for injection.
- Author:
Jun-jie ZHOU
1
;
Zong-hai HUANG
;
Jin-long YU
;
Zhou LI
;
Guang-jun ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Abdomen; surgery; Adolescent; Adult; Aged; Agkistrodon; metabolism; Animals; Batroxobin; administration & dosage; therapeutic use; Blood Coagulation; drug effects; Blood Loss, Surgical; prevention & control; Hemostasis, Surgical; methods; Hemostatics; administration & dosage; therapeutic use; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome; Young Adult
- From: Journal of Southern Medical University 2007;27(5):644-646
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of hemocoagulase acutus for injection and determine its curative dose.
METHODSForty-five patients on abdominal surgeries were randomly allocated into 2 study groups and 1 control group. Thirty minutes before the operation, the patients in the study groups received intravenous hemocoagulase acutus at 1 U and 2 U, respectively, and control group had no treatment. The hemostatic time, hemorrhagic volume, and hemoagglutination were observed in all the groups.
RESULTSThe average hemorrhagic volume and hemorrhagic volume per square were significantly lower in the two study groups than in the control group (P<0.05), and the average hemorrhagic volume per square were significantly lower in study group 2 U than in the 1 U group (P<0.05). No significant differences were found in adverse effects between the 3 groups.
CONCLUSIONHemocoagulase acutus for injection has good hemostatic effect for controlling capillary hemorrhage at the abdominal incisions and can be safely used in the surgical patients.
